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Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukaemia
W.Y. Au1, C.R. Kumana1, M. Kou1, R. Mak2, G.C.F. Chan3, C.W. Lam4, Y.L. Kwong1
Departments of Medicine1, Pharmacy2 and Paediatrics3, Queen Mary Hospital, and Department of Clinical Pathology4,
Chinese University of Hong Kong, Prince of Wales Hospital.
Introdution. Arsenic trioxide (As2O3) induces a remission in over 90% of patients with relapsed acute promyelocytic
leukaemia (APL). To date, only the intravenous (i.v.) preparation of As2O3 has been used. We have recently
developed an oral preparation of As2O3 that achieves blood levels of elemental arsenic comparable with those
of i.v. As2O3 (Eur J Clin Pharmacol Oct 11, 2002 online). In this study, the efficacy and safety of oral As2O3 were
evaluated.
Materials and methods. Twelve consecutive unselected patients with relapsed APL were treated with oral-As2O3
(10 mg/day) until remission.
Results. Eight patients in first relapse achieved a second complete remission (CR2) after a median of 37 days of
oral-As2O3. Subsequent consolidation with idarubicin or oral-As2O3 plus all-trans retinoic acid (ATRA, 45 mg/m2/day)
resulted in continuous CR2 in seven patients (median follow-up: 12 months). Four patients in second relapse (from
CR2 induced by intravenous-As2O3) achieved CR3 after a median of 31 days of treatment with oral-As2O3/ATRA.
After subsequent consolidation with oral-As2O3/ATRA, all had remained in CR3 at a median follow-up of 14
months. Patients in CR were negative for PML/RARA 3-6 months post oral-As2O3 treatment. Toxicity of oral-As2O3
was mild, including leucocytosis without the ATRA syndrome, skin rashes, headache and transient liver function
derangement. Cardiac arrhythmias were not observed.
Conclusion. These results show that oral-As2O3 is a safe and efficacious treatment for relapsed APL.
Effect of arsenic trioxide on the cell proliferation of human neuroblastoma cell
line IMR-32 cells
W.M.W. Cheung, P.W.K. Chu & Y.L. Kwong.
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
Introduction: Neuroblastoma is one of the commonest pediatric tumors and is derived from neural crest precursors
cells. Spontaneous regression and maturation of neuroblastoma to ganglioneuroma suggest that differentiation
therapy might be potentially useful. Arsenic trioxide (As2O3) is an effective therapeutic agent for acute promyelocytic
leukemia (APL), and induces both differentiation and apoptosis of leukemic cells in vivo. However, the underlying
molecular mechanisms are not fully understood. In this study, we used a human neuroblastoma cell line, IMR-32,
as our in vitro model to study the potential application of As2O3 as a differentiation agent for neuroblastoma.
Method: IMR-32 cells were treated with increasing concentrations of As2O3 (0.1 to 5.0 µM). MTT assays were
performed to examine the effect of As2O3 on cellular proliferation. Western blot analysis was performed to identify
the potential signaling molecules involved.
Results: At high concentrations of As2O3, cellular proliferation of IMR-32 was significantly inhibited (~35% at 1.5 µM
and ~78% at 5.0 µM). Western blot analysis of differentiation markers suggested that As2O3 induced differentiation
of IMR-32 cells at low concentrations (≤2.5 µM), but led to apoptosis at high concentrations (5.0 µM). As2O3
induced the phosphorylation of p42/44 MAP kinases (Erk1/2) and protein kinase C (PKC) in a dose and time-
dependent manner. Pre-treatment of IMR-32 cells with Ro-31-8220 (1 µM), a specific PKC inhibitor, partially
blocked the effect of As2O3.
Conclusion: We conclude that As2O3 is capable of inhibiting the cell proliferation of a human neuroblastoma cell
line IMR-32 via cell differentiation and apoptosis. Signaling molecules such as Erk1/2 and PKC might play crucial
roles during the anti-proliferation action of As2O3. The study was supported by the Kadoorie Charitable Fund.
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